Melissa Gebhardt’s Post

A potential treatment for motor neurone disease could be around the corner, after a new drug developed by The University of Queensland produced successful results in a human clinical trial. 👨🔬 The UQ spin-out company NuNerve announced its lead drug candidate NUN-004 was safe and effective in the Phase 1 study. Read: https://bit.ly/4ivpUIe #UQ #QBI #news #research #mnd

Will you be at #ARVO2024? Let’s connect!   Join me for one of the many poster presentations featuring new and updated data demonstrating the potential efficacy of our lead drug candidate for Meibomian Gland Dysfunction (MGD). Session details are in the link below. 

If you are developing a medicine for a rare disease and have more questions about Orphan Drug Designation, watch our webinar “Orphan Drug Designation - Do You Have the Global Strategy?” now on YouTube! Access the online recording of the webinar using the link below: https://lnkd.in/dWyuaS2e The webinar will help you understand the benefits of Orphan Drug Designation, providing insights on how to use OD as a tool for significant financial discounts or additional scientific support. You will also gain a deeper understanding of the advantages of applying simultaneously to ODs globally and the specific  benefits provided by each region. For any further questions, please contact our expert,  Liam Spencer. #LumisInternational #OrphanDrugDesignation #OrphanMedicine #OrphanDesignation

Did you know that Worldwide partners with over 115 rare disease organizations around the globe to help leverage shared expertise so we can improve patient outcomes and accelerate breakthroughs in drug development? Learn more about these partnerships and how these organizations are helping make an impact on rare disease clinical research in our blog: https://bit.ly/4fyJOAv

First-of-its-kind Human Trial to be revealed at ASCO 2024. First-in-human trials act as the bridge for advancing new, promising drug candidates and are primarily conducted to establish the safe dosage range for subsequent clinical development. Numerous stakeholders are actively engaged in discussing their first-in-human trial data findings. This data appears highly compelling, particularly in the context of the innovative class of therapies currently in development within the pipeline. For more captivating insights, visit: https://lnkd.in/dj6Za_QE #FirstInHuman #ClinicalTrials #DrugDevelopment #SafeDose #MedicalResearch #TherapeuticInnovation #PipelineProgress #ClinicalData #HealthcareAdvancement

Did you know that Worldwide partners with over 115 rare disease organizations around the globe to help leverage shared expertise so we can improve patient outcomes and accelerate breakthroughs in drug development? Learn more about these partnerships and how these organizations are helping make an impact on rare disease clinical research in our blog: https://bit.ly/4ey5ziq

If you are developing a medicine for a rare disease and have more questions about Orphan Drug Designation, watch our webinar “Orphan Drug Designation - Do You Have the Global Strategy?” now on YouTube! Access the online recording of the webinar using the link below: https://lnkd.in/dWyuaS2e The webinar will help you understand the benefits of Orphan Drug Designation, providing insights on how to use OD as a tool for significant financial discounts or additional scientific support. You will also gain a deeper understanding of the advantages of applying simultaneously to ODs globally and the specific  benefits provided by each region. For any further questions, please contact our expert,  Liam Spencer. #LumisInternational #OrphanDrugDesignation #OrphanMedicine #OrphanDesignation

We're developing an autoimmune panel that covers the major and minor immune populations in cytometry important to drug developers. You’ll likely be able to get a 10X increase in resolution in the number of populations with our tools. If you're frustrated with the level of detail you are getting in a 🦕 TBNK panel and tired of paying custom panel build fees, DM me to connect at #ACR24 this weekend. What’s in it for you? Your input will directly influence the most comprehensive autoimmune cytometry panel for clinical trials. The markers you suggest will likely set the standard for cytometry analysis in autoimmune.

Did you know that Worldwide partners with over 115 rare disease organizations around the globe to help leverage shared expertise so we can improve patient outcomes and accelerate breakthroughs in drug development? Learn more about these partnerships and how these organizations are helping make an impact on rare disease clinical research in our blog: https://bit.ly/3ZnNYFw